Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Carbohydrate doai
Reexamination Certificate
2011-04-05
2011-04-05
McGarry, Sean R (Department: 1635)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Carbohydrate doai
C435S006120, C536S023100, C536S024100, C536S024500
Reexamination Certificate
active
07919474
ABSTRACT:
A therapeutic and/or cosmetic formulation comprising at least one anti-sense polynucleotide to a connexin protein together with a pharmaceutically acceptable carrier or vehicle is useful in site specific down regulation of connexin protein expression, particularly in reduction of neuronal cells death, wound healing, reduction of inflammation, decrease of scar formation and skin rejuvenation and thickening.
REFERENCES:
patent: 5998148 (1999-12-01), Bennett et al.
patent: WO9619194 (1996-06-01), None
patent: WO9824797 (1998-06-01), None
Singh et al. Cytobios vol. 91:103-123, 1997.
Agrawal, S., TIBTECH vol. 14:376-387 Oct. 1996.
Branch, A., TIBS vol. 23:45-50, Feb. 1998.
Jen et al., Stem Cells, vol. 18:307-319, 2000.
Qiu et al., Current Biology, vol. 13:1697-1703, Sep. 30, 2004.
Hodgins, M., Journal of Investigative Dermatology, vol. 122(5):ix-x, 2004.
Ruch, R. et al., Molecular Carcinogenesis 14:269-274, 1995.
Goliger, J. et al., Molecular Biology of the Cell 6:1491-1501, 1995.
Moore et al., Am J. Physiology, vol. 265, No. 1, pp. C1371-C1388, 1994.
European Patent Office, Search Report for Application No. 05016736.0, Dec. 19, 2005.
Grazul-Bilska et al., Abstract, Biology Reproduction, vol. 58, No. 1, p. 78, 1998.
Davis et al., “Modulation of Connexin43 Expression: Effects on Cellular Coupling”, Journal of Cardiovascular Electrophysiology, 1995.
Rozenthal et al., “Stable Transfection with Connexin43 Inhibits Neuronal Differentiation of PC12 Cells”, Oct. 25, 1997, U.S.
Becker et al., “Connexin Alpha1 and Cell Proliferation in the Developing Chick Retina” Experimental Neurology, vol. 156, No. 2, Apr. 1999, pp. 326-332, XP002347187 ISSN: 0014-4886.
Green et al., “Spatiotemporal Depletion of Connexins Using Antisense Oligonucleotides.” Methods in Molecular Biology (Clifton, N.J.) 2001, vol. 154, 2001, pp. 175-185, XP008053224 ISSN: 1064-3745.
Franteseva, M. et al., “Ischemia-Induced Brain Damage Depends on Specific Gap-Junctional Coupling” Journal of Cerebral Blood Flow and Metabolism, vol. 22, No. 4, Apr. 2002, pp. 453-462, XP008053227 ISSN: 0271-678X.
Ratkay-Traub et al., “Regeneration of Rabbit Cornea Following Excimer Laser Photorefractive Keratectomy: A Study on Gap Junctions, Epithelial Junctions and Epidermal Growth Factor Receptor Expression in Correlation with Cell Proliferation”, Experimental Eye Research, vol. 73, No. 3, Sep. 2001, pp. 291-302, XP002347188 ISSN: 0014-4835.
Baldwin, H. et al., “Growth Factors in Corneal Wound Healing Following. Refractive Surgery: A Review” Acta Opthalmologica Scandinavica, vol. 80, No. 3, Jun. 2002, pp. 238-247, XP002347189 ISSN:1395-3907.
Willecke, K. et al., “Structural and Functional Diversity of Connexin Genes in the Mouse and Human Genome” Biological Chemistry, vol. 383, No. 5, May 2002, pp. 725-737, XP008053223 ISSN: 1431-6730.
Santoro, S. et al., “A Genome Purpose RNA-Cleaving DNA Enzyme” Proceedings of the National Academy of Sciences USA, vol. 94, Apr. 1997, pp. 4262-4266, XP001009844 ISSN: 0027-8424.
Becker David Laurence
Green Richard Colin
Coda Therapeutics, Inc.
Duane Morris LLP
McGarry Sean R
LandOfFree
Formulations comprising antisense nucleotides to connexins does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Formulations comprising antisense nucleotides to connexins, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Formulations comprising antisense nucleotides to connexins will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2707494